A. If the non-UK institution IS NOT engaged in the research:
Submit a letter from the appropriate administrator of the non-UK institution (on the facility’s letterhead stationery), that addresses the following items:
- Agreement of the institution’s administration for the study to be conducted at that site;
- Review of the project by someone at the facility with respect to the issues of appropriateness for its human subject population, and adequacy of the facility to perform the procedures as approved by the UK IRB (if applicable).
B. If the non-UK institution IS engaged in the research AND UK will serve as the relied-upon IRB for oversight of the project*:
Submit a letter from the appropriate administrator of the non-UK institution (on the facility’s letterhead stationery), that addresses the following items:
- Agreement of the institution’s administration for the study to be conducted at that site;
- Review of the project by someone at the facility with respect to the issues of appropriateness for its human subject population, and adequacy of the facility to perform the procedures as approved by the UK IRB. For FDA regulated research, the non-UK institution attests to, or provides verification of, site’s adequacy to execute the clinical protocol requirements (e.g., equipment, emergency/specialized care, test article security/accountability);
- Written confirmation that the facility personnel have the appropriate expertise to carry out the research procedures as reviewed and approved by the IRB.For FDA regulated research, the non-UK institution attests to, or provides verification of, appropriate qualifications of applicable clinical investigators (e.g., credentials, licensure, training, expertise, experience, and/or inspection history);
- Assurance that personnel from the facility who are involved in data collection have appropriate training in human subject research protection.
- A fully executed IRB Authorization Agreement (IAA) or Individual Investigator Agreement (IIA), which can be determined at the discretion of UK’s Reliance Team and/or the UK IRB, in conjunction with the non-UK institution.
*If the participating non-UK site has its own IRB and that IRB will review and approve the protocol for its own location, then you may submit a copy of the IRB approval from that site in place of a letter of support & local context.